AlphaCrest Capital Management’s Integra LifeSciences IART Stock Holding History

AlphaCrest Capital Management’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-21,160	Closed	-$896K	–	543
2022 Q3	$896K	Sell	21,160 -13,740	-39%	-$704K	0.05%	684
2022 Q2	$1.89M	Buy	34,900 +457	+1%	+$27.4K	0.09%	345
2022 Q1	$2.21M	Buy	34,443 +24,465	+245%	+$1.61M	0.12%	209
2021 Q4	$668K	Sell	9,978 -2,625	-21%	-$178K	0.02%	976
2021 Q3	$863K	Buy	12,603 +8,963	+246%	+$633K	0.04%	671
2021 Q2	$248K	Buy	3,640 +645	+22%	+$45.6K	0.01%	1157
2021 Q1	$207K	Sell	2,995 -3,379	-53%	-$229K	0.01%	1134
2020 Q4	$414K	Sell	6,374 -4,633	-42%	-$249K	0.03%	761
2020 Q3	$520K	Buy	11,007 +4,936	+81%	+$235K	0.06%	563
2020 Q2	$285K	Sell	6,071 -10,578	-64%	-$520K	0.05%	656
2020 Q1	$744K	Buy	+16,649	New	+$874K	0.09%	396
2019 Q4	–	Sell	-13,777	Closed	-$828K	–	1302
2019 Q3	$828K	Buy	13,777 +5,745	+72%	+$342K	0.05%	672
2019 Q2	$449K	Buy	8,032 +4,053	+102%	+$209K	0.04%	735
2019 Q1	$222K	Buy	+3,979	New	+$203K	0.03%	753

Other funds holding IART

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

AlphaCrest Capital Management's IART Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Integra LifeSciences (IART) in Q4 2022, closing a stake of 21,160 shares — an estimated $896K sold.

AlphaCrest Capital Management first reported a position in IART in Q1 2019 and held it in 14 quarters. The position peaked at $2.21M in Q1 2022. 281 funds tracked by Wall St. Rank hold IART as of Q4 2022.

AlphaCrest Capital Management reported no remaining Integra LifeSciences position as of Q4 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 21,160 Integra LifeSciences shares in Q4 2022, an estimated $896K.
AlphaCrest Capital Management first reported a position in Integra LifeSciences in Q1 2019 and held it in 14 quarters.
AlphaCrest Capital Management's Integra LifeSciences position peaked at $2.21M in Q1 2022.
281 funds tracked by Wall St. Rank held Integra LifeSciences as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.